Trabectedin in ovarian cancer: could we expect more?

Affiliations

¹ IOSI Oncology, San Giovanni Hospital, Bellinzona, Switzerland; Progetto Montabone, Fondazione IRCCS, National Cancer Institute, Milano, Italy. Electronic address: cristiana.sessa@eoc.ch.
² Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy.

Free article

Editorial

C Sessa et al. Ann Oncol. 2011 Jan.

Free article

. 2011 Jan;22(1):7-8.

doi: 10.1093/annonc/mdq641. Epub 2010 Nov 8.

¹ IOSI Oncology, San Giovanni Hospital, Bellinzona, Switzerland; Progetto Montabone, Fondazione IRCCS, National Cancer Institute, Milano, Italy. Electronic address: cristiana.sessa@eoc.ch.
² Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy.

No abstract available

Comment on

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Poveda A, et al. Ann Oncol. 2011 Jan;22(1):39-48. doi: 10.1093/annonc/mdq352. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643862 Free PMC article. Clinical Trial.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, Lebedinsky C, Parekh T, Santabárbara P, Park YC, Nieto A, Poveda A. Kaye SB, et al. Ann Oncol. 2011 Jan;22(1):49-58. doi: 10.1093/annonc/mdq353. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643863 Free PMC article. Clinical Trial.